Press releases
- Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
- NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
- Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
- Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
- Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
- CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
- Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
- Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
More ▼
Key statistics
On Tuesday, Legend Biotech Corp (9LB:DEU) closed at 39.00, 0.52% above its 52-week low of 38.80, set on May 14, 2024.
52-week range
Open | 41.40 |
---|---|
High | 42.00 |
Low | 39.00 |
Bid | 39.40 |
Offer | 39.80 |
Previous close | 41.80 |
Average volume | 84.00 |
---|---|
Shares outstanding | 182.28m |
Free float | 180.09m |
P/E (TTM) | -- |
Market cap | 7.83bn USD |
EPS (TTM) | -2.60 USD |
Data delayed at least 15 minutes, as of May 21 2024.
More ▼